2003
DOI: 10.1016/s1098-612x(03)00053-6
|View full text |Cite
|
Sign up to set email alerts
|

Clinical use of dexmedetomidine as premedicant in cats undergoing propofol–sevoflurane anaesthesia

Abstract: The purpose of this report was to evaluate the cardiorespiratory effects and efficacy of dexmedetomidine as a premedicant agent in cats undergoing ovariohysterectomy anaesthetized with propofol-sevoflurane. Cats were randomly divided into two groups of eight animals each. Dexmedetomidine (0.01 mg/kg) or 0.9% saline was administered intravenously (D and S, respectively). After 5 min, propofol was administered intravenously and anaesthesia was maintained with sevoflurane. Heart and respiratory rates, arterial bl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
21
0
4

Year Published

2008
2008
2016
2016

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 27 publications
(28 citation statements)
references
References 15 publications
3
21
0
4
Order By: Relevance
“…1". As reported in previous studies (Kallio et al, 1989;Ansah et al, 1998;Lamont et al, 2001;Mendes et al, 2003;Selmi et al, 2003) marked decrease in heart rate and cardiac output, increase in total vascular resistance and transient mild changes in blood pressure, are expected dose-dependent effects of dexmedetomidine administration. The effect of alpha 2 agonist on blood pressure are defined by two stages: An initial phase characterized by peripheral vasoconstriction, increase blood pressure and reflex bradycardia and another subsequent phase with a reduction of sympathetic tone and hypotension (Herbert et al, 2007).…”
Section: Discussionsupporting
confidence: 64%
See 1 more Smart Citation
“…1". As reported in previous studies (Kallio et al, 1989;Ansah et al, 1998;Lamont et al, 2001;Mendes et al, 2003;Selmi et al, 2003) marked decrease in heart rate and cardiac output, increase in total vascular resistance and transient mild changes in blood pressure, are expected dose-dependent effects of dexmedetomidine administration. The effect of alpha 2 agonist on blood pressure are defined by two stages: An initial phase characterized by peripheral vasoconstriction, increase blood pressure and reflex bradycardia and another subsequent phase with a reduction of sympathetic tone and hypotension (Herbert et al, 2007).…”
Section: Discussionsupporting
confidence: 64%
“…Dexmedetomidine is a relatively new alpha 2 adrenergic agonist; it is the active optical enantiomer isolated from the racemic compound medetomidine (MacDonald et al, 1991;Selmi et al, 2003). Efficacy of dexmedetomidine has been demonstrated by several studies in cats (Ansah et al, 1998;Mendes et al, 2003;Granholm et al, 2006) however dexmedetomidine has also important cardiovascular and respiratory side effects, such as peripheral vascular resistance increase, bradycardia, decrease in cardiac output and respiratory depression (Pypendop et al, 2011). These effects are the result of a decrease in sympathetic activity and a simultaneous parasympathetic increase in the Central Nervous System (CNS) plus the vagal reflex originating in the baroreceptors in response to the initial hypertension caused by alpha 2 agonist.…”
Section: Introductionmentioning
confidence: 99%
“…Clinical studies in dogs and cats have shown that the pharmacodynamic effects of DEX are twice as potent as the MED racemic mixture, therefore DEX is administered at half the dose of MED for sedation; as for MED, the sedative and analgesic effects of DEX are antagonised by atipamezole (Cullen 1996;Ansah et al 1998Ansah et al , 2000Kuusela et al 2000;Mendes et al 2003;Granholm et al 2006). DEX has been approved for clinical use in dogs and cats in Italy since 2008, and we immediately started to use it for dog and cat sedation.…”
Section: Introductionmentioning
confidence: 99%
“…These differences in midazolam administration might explain the contrasting results. Another probable explanation for these differences is the rate of propofol administration, which directly affects the induction dose (SHORT; BUFALARI, 1999;MENDES et al, 2003;TABOADA;MURISON, 2010). Studies comparing dosages did not describe the rate of administration (BREARLEY el al., 1988;MORGAN;LEGGE, 1989;WEAVER;RAPTOPOULOS, 1990).…”
Section: Discussionmentioning
confidence: 99%